These procedures yielded NPs in sizes of 71532nm and 74742nm when z-DEVD-FMK or bFGF were loaded, respectively. The experiments were performed on 75 Swiss hvidf?dning, male mice (2530g). bFGF-loaded NPs were not conjugated with all the targeting antibody, which enables them to mix the BBB. Nanoparticles targeted to brain are promising drug carriers to transport large as well as small BBB-impermeable therapeutics intended for neuroprotection against stroke. Keywords: cerebrovascular disease/stroke, caspases, growth factors/cytokines, nanoparticles, neuroprotection == Introducton == Recent research has disclosed that cell death in ABBV-744 acute as well as chronic neurodegenerative diseases involves common mechanisms such as caspase activation. 1, 2, 3, 4, 5Therefore, inhibitors of caspases (e. ABBV-744 g., benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-fluoromethylketone (z-DEVD-FMK)) appear to be attractive therapeutic focuses on for a wide range of neurologic diseases including stroke. 6, 7, 8Unfortunately, most of the inhibitor providers are small peptides that cannot mix the bloodbrain barrier (BBB). However , growth factors (e. g., basic fibroblast growth factor (bFGF)) suppress cell death by acting at several points on death pathways and, additionally , promote regeneration. 9, 10, 11These features get them to promising providers for treatment of stroke and other neurodegenerative diseases. Unfortunately, these large peptides too cannot penetrate the brain tissue when systemically administrated. Although it continues to be proposed that opening from the BBB after ischemia could allow large molecules such as bFGF to enter the brain, recent studies examining the BBB leakage topographically have shown that early leakage is only seen in the deeply ischemic ABBV-744 core areas but not in the potentially salvageable penumbra. 12, 13, 14 Promoting cell survival while inhibiting death effectors is a potentially promising neuroprotective approach that may provide ingredient synergy between these two groups of drugs. Indeed, Maet al15demonstrated that both z-DEVD-FMK and bFGF could reduce infarct size when given intracerebroventricularly and that their combined government had a synergistic effect; not only the infarct reduction was greater but also the therapeutic time window was prolonged compared with their individual use. Therefore , the development of an effective brain delivery system intended for peptides is needed to translate these promising experimental achievements to clinic. Brain-targeted nanoparticles (NPs) can transport large amounts of BBB-impermeable providers across the BBB on systemic administration. 16, 17We previously demonstrated that chitosan NPs loaded with z-DEVD-FMK and conjugated with antitransferrin receptor-1 monoclonal antibody (TfRMAb) rapidly crossed the BBB upon systemic government to mice by way of transferrin receptor-mediated transcytosis and provided neuroprotection against focal cerebral ischemia. 18However, loading large peptides such as bFGF to NPs and their transport to the brain in an active type and adequate concentrations remained a challenge. In the present study, we have first developed the conditions to load bFGF to chitosan NPs and then showed that they reduced ischemic injury on systemic administration. Next, we investigated if we could obtain an additive protecting activity by combined government of z-DEVD-FMK and bFGF-loaded NPs and whether this approach could provide a prolonged therapeutic window. We have also exhibited activation from the downstream pathways in bFGF signaling to confirm that bFGF was transported in adequate concentrations just like the inhibition of caspase-3 activity with z-DEVD-FMK-loaded NPs as we previously showed. 18Finally, we verified that neuroprotection was mediated by transcytosis of peptide-loaded NPs across the endothelium by inhibiting transcytosis with imatinib. 19Importantly, the targeted brain delivery of bFGF-loaded NPs provided not only neuroprotection but also ~300 occasions reduction in the amount of the peptide administered to the mouse compared with the systemic administration of plain bFGF, offering a great advantage to lessen APAF-3 systemic adverse effects. 20 == Materials and Methods == Preparation and characterization from the TfRMAb-conjugated or unconjugated.